Skip to main content

Table 1 Patients’ Characteristics According to Interim PET/CT Status

From: Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial

Characteristic

interim PET/CT

Negative, n = 115

interim PET/CT Positive, n = 14

Total,

N = 129

N 51334

χ2

P

 

4R-CHOP+2R,n = 63

6R-CHOP,

n = 52

    

Age, year

      

Median (range)

47.9 (18–74)

53 (24–77)

48.5 (20–70)

50 (18–77)

  

≤60y

51 (81)

42 (80.8)

10 (71.4)

103 (79.8)

0.23

0.63

> 60y

12 (19)

10 (19.2)

4 (28.6)

26 (20.2)

  

Gender

      

Male

36 (57.1)

26 (50)

10 (71.4)

72 (55.8)

0.92

0.33

Female

27 (42.9)

26 (50)

4 (28.6)

57 (44.2)

  

Extranodal involvement

      

No

63 (100)

1 (1.9)

6 (42.9)

70 (54.3)

0.39

0.53

Yes

0

51 (98.1)

8 (57.1)

59 (45.7)

  

Ann Arbor Stage

      

I

27 (42.9)

25 (48.1)

4 (28.6)

56 (43.4)

0.81

0.37

II

36 (57.1)

27 (51.9)

10 (71.4)

73 (56.6)

  

ECOG PS

      

0

40 (63.5)

27 (51.9)

6 (42.9)

73 (56.6)

0.65

0.41

1

23 (36.5)

25 (48.1)

8 (57.1)

56 (43.4)

  

B symptoms

      

No

61 (96.8)

46 (88.5)

13 (92.9)

120 (93)

0.28

0.59

Yes

2 (3.2)

6 (11.5)

1 (7.1)

9 (7)

  

LDH level

      

Normal

60 (95.2)

51 (98.1)

11 (78.6)

122 (94.6)

4.72

0.03*

Elevated

3 (4.8)

1(1.9)

3 (21.4)

7 (5.4)

  

IPI score

      

0–1

61 (96.8)

51 (98.1)

14 (100)

116

0.11

0.74

2

2(3.2)

1 (1.9)

0 (0)

3 (2.3)

  
  1. Values shown are n (%) or median (range)
  2. Abbreviations: PS Performance Status, LDH Lactate Dehydrogenase, IPI International Prognostic Index
  3. Chi-square test was applied to detect differences of characteristics between interim PET/CT positive (n = 14) and negative ones (n = 115). * P < 0.05